glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results Glucagon-Like Peptide-1 Use in People Living with Type 2 Diabetes Mellitus and Chronic Disease: A Narrative Review of the Key Evidence with Practical Considerations | Diabetes Therapy Long-term kidney outcomes of semaglutide

Poll: 1 in 8 adults say they are currently taking a GLP-1 drug for weight loss, diabetes, or another condition, even as half say the drugs are difficult to afford, KFF (2025) The relationship between dietary habits and menstruation problems in women: a cross-sectional study, BMC Womens Health (2024) Systemic inflammation and menstrual cycle length in a prospective cohort study, American Journal of Obstetrics & Gynecology (2023) Do GLP-1 weight loss drugs affect the menstrual cycle

These early tests are crucial for identifying any potential toxic effects and refining the formulation

It is the first FDA- approved drug since 2017 for chronic weight management in overweight adults with obesity

Elsaid: The ESSENCE trial showed that semaglutide improves liver histology in fibrotic MASH, which is why the FDA approved it for that use